In recent trading, shares of CONMED Corp (CNMD) surpassed the average 12-month analyst target price of $111.62, currently trading at $111.99 per share. Analysts are now weighing potential action, including downgrades or upward adjustments, influenced by recent positive developments for the company.
The target estimates from eight analysts cover a range from a low of $96.00 to a high of $124.00, with a standard deviation of $10.42. Currently, CONMED Corp has four strong buy ratings, one buy rating, and three hold ratings, with an average rating of 1.88 on a scale where 1 is “Strong Buy” and 5 is “Strong Sell.”
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
